Y Intercept Hong Kong Ltd Buys New Position in BioAge Labs, Inc. $BIOA

Y Intercept Hong Kong Ltd purchased a new stake in BioAge Labs, Inc. (NASDAQ:BIOA) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 201,337 shares of the company’s stock, valued at approximately $3,521,000.

Several other hedge funds have also recently added to or reduced their stakes in BIOA. Adage Capital Partners GP L.L.C. acquired a new stake in shares of BioAge Labs in the 4th quarter valued at $13,892,000. Janus Henderson Group PLC acquired a new stake in shares of BioAge Labs during the fourth quarter worth about $5,406,000. Millennium Management LLC grew its holdings in shares of BioAge Labs by 749.8% during the third quarter. Millennium Management LLC now owns 306,552 shares of the company’s stock worth $1,803,000 after buying an additional 270,479 shares during the last quarter. Sphera Funds Management LTD. acquired a new position in BioAge Labs in the 4th quarter valued at about $3,215,000. Finally, Invesco Ltd. purchased a new position in BioAge Labs during the 4th quarter worth $3,025,000.

BioAge Labs Stock Down 3.0%

Shares of BIOA stock traded down $0.74 during trading on Tuesday, reaching $24.10. 110,401 shares of the company’s stock were exchanged, compared to its average volume of 612,557. The firm’s fifty day moving average price is $18.84 and its 200-day moving average price is $18.42. BioAge Labs, Inc. has a twelve month low of $4.11 and a twelve month high of $25.95. The stock has a market capitalization of $1.07 billion, a PE ratio of -10.05 and a beta of 0.61.

BioAge Labs (NASDAQ:BIOA) last released its quarterly earnings data on Friday, May 8th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.71) by $0.19. The firm had revenue of $2.77 million for the quarter. BioAge Labs had a negative net margin of 871.75% and a negative return on equity of 29.40%. As a group, analysts anticipate that BioAge Labs, Inc. will post -2.68 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on BIOA shares. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. BTIG Research began coverage on shares of BioAge Labs in a research report on Wednesday, May 13th. They set a “buy” rating and a $40.00 price target for the company. Wall Street Zen downgraded shares of BioAge Labs from a “hold” rating to a “sell” rating in a research report on Sunday, May 17th. Citigroup boosted their price target on BioAge Labs from $15.00 to $52.00 and gave the company a “buy” rating in a report on Tuesday, March 10th. Finally, Roth Capital started coverage on shares of BioAge Labs in a report on Wednesday, May 27th. They set a “buy” rating and a $36.00 target price on the stock. Six research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.50.

BioAge Labs Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.